Article: Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleAdefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
AuthorsSchiff, E12
Lai, CL21
Hadziyannis, S57
Nuehaus, P
Terrault, N1
Colombo, M46
Tillmann, H32
Samuel, D3
Zuezem, S29
Villenueve, JP26
Arteburn, S34
BorrotoEsoda, K34
Brosgart, C34
Chuck, S34
Shakil, AO28
Fung, J28
Alberti, A5
Lok, A13
Picciotto, A15
Torre, F15
Riely, C7
Trepo, C51
Bizollon, T51
BottaaFridlund, D19
Gerolami, R19
Douglas, D30
Ranjan, D9
Faust, D11
Trojan, J11
Gane, E44
Villa, E31
Boarino, M31
Sokal, E25
Starkel, P25
Bonino, F39
Maurizio, B39
Gordon, F48
Pratt, J48
Berr, F22
Schiefke, I22
McCaughan, G24
Strasser, S24
Dusheiko, G2
Pageaux, GP49
Larrey, D49
Pastore, G17
Santantonio, T17
Alexander, G42
Woodall, T42
Van Vlierberghe, H59
Colle, I59
Harley, H54
Guggenheim, J58
MyxStaccini, A58
Metreau, JM53
Mavier, P53
Vierling, J55
Tran, T55
Girgrah, N38
Nyberg, L4
Yuen, MF40
Ma, M27
Balnco, MD16
Merli, M50
Tanzilli, P50
Angelico, M41
Di Paolo, D41
Rizzetto, M52
Marzano, A52
Lampertico, P
Prieto, M37
Berenguer, M37
Felder, M36
Sterneck, M45
Willems, M45
Charlton, M10
Gunneson, T10
Ritter, M6
Voight, M18
Swift, J18
Shiffman, M33
Tassopoulos, N56
Klissas, I56
Naourmov, N2
Chamouard, P20
Marcellin, P60
Durand, F60
Angus, P47
Nathan, C47
Toniutto, P23
Fumo, E23
Andreone, P35
Cursaro, C35
Barcena, R14
Hoz, FG14
Zachoval, R43
Christina, M43
De Man, RA8
Metselaar, H8
Issue Date2007
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
CitationLiver Transplantation, 2007, v. 13 n. 3, p. 349-360 [How to Cite?]
DOI: http://dx.doi.org/10.1002/lt.20981
AbstractWait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<l,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among postransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%. 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among parents who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patiends who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe at wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg. © 2007 AASLD.
ISSN1527-6465
2011 Impact Factor: 3.386
2011 SCImago Journal Rankings: 0.305
DOIhttp://dx.doi.org/10.1002/lt.20981
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorSchiff, E
dc.contributor.authorLai, CL
dc.contributor.authorHadziyannis, S
dc.contributor.authorNuehaus, P
dc.contributor.authorTerrault, N
dc.contributor.authorColombo, M
dc.contributor.authorTillmann, H
dc.contributor.authorSamuel, D
dc.contributor.authorZuezem, S
dc.contributor.authorVillenueve, JP
dc.contributor.authorArteburn, S
dc.contributor.authorBorrotoEsoda, K
dc.contributor.authorBrosgart, C
dc.contributor.authorChuck, S
dc.contributor.authorShakil, AO
dc.contributor.authorFung, J
dc.contributor.authorAlberti, A
dc.contributor.authorLok, A
dc.contributor.authorPicciotto, A
dc.contributor.authorTorre, F
dc.contributor.authorRiely, C
dc.contributor.authorTrepo, C
dc.contributor.authorBizollon, T
dc.contributor.authorBottaaFridlund, D
dc.contributor.authorGerolami, R
dc.contributor.authorDouglas, D
dc.contributor.authorRanjan, D
dc.contributor.authorFaust, D
dc.contributor.authorTrojan, J
dc.contributor.authorGane, E
dc.contributor.authorVilla, E
dc.contributor.authorBoarino, M
dc.contributor.authorSokal, E
dc.contributor.authorStarkel, P
dc.contributor.authorBonino, F
dc.contributor.authorMaurizio, B
dc.contributor.authorGordon, F
dc.contributor.authorPratt, J
dc.contributor.authorBerr, F
dc.contributor.authorSchiefke, I
dc.contributor.authorMcCaughan, G
dc.contributor.authorStrasser, S
dc.contributor.authorDusheiko, G
dc.contributor.authorPageaux, GP
dc.contributor.authorLarrey, D
dc.contributor.authorPastore, G
dc.contributor.authorSantantonio, T
dc.contributor.authorAlexander, G
dc.contributor.authorWoodall, T
dc.contributor.authorVan Vlierberghe, H
dc.contributor.authorColle, I
dc.contributor.authorHarley, H
dc.contributor.authorGuggenheim, J
dc.contributor.authorMyxStaccini, A
dc.contributor.authorMetreau, JM
dc.contributor.authorMavier, P
dc.contributor.authorVierling, J
dc.contributor.authorTran, T
dc.contributor.authorGirgrah, N
dc.contributor.authorNyberg, L
dc.contributor.authorYuen, MF
dc.contributor.authorMa, M
dc.contributor.authorBalnco, MD
dc.contributor.authorMerli, M
dc.contributor.authorTanzilli, P
dc.contributor.authorAngelico, M
dc.contributor.authorDi Paolo, D
dc.contributor.authorRizzetto, M
dc.contributor.authorMarzano, A
dc.contributor.authorLampertico, P
dc.contributor.authorPrieto, M
dc.contributor.authorBerenguer, M
dc.contributor.authorFelder, M
dc.contributor.authorSterneck, M
dc.contributor.authorWillems, M
dc.contributor.authorCharlton, M
dc.contributor.authorGunneson, T
dc.contributor.authorRitter, M
dc.contributor.authorVoight, M
dc.contributor.authorSwift, J
dc.contributor.authorShiffman, M
dc.contributor.authorTassopoulos, N
dc.contributor.authorKlissas, I
dc.contributor.authorNaourmov, N
dc.contributor.authorChamouard, P
dc.contributor.authorMarcellin, P
dc.contributor.authorDurand, F
dc.contributor.authorAngus, P
dc.contributor.authorNathan, C
dc.contributor.authorToniutto, P
dc.contributor.authorFumo, E
dc.contributor.authorAndreone, P
dc.contributor.authorCursaro, C
dc.contributor.authorBarcena, R
dc.contributor.authorHoz, FG
dc.contributor.authorZachoval, R
dc.contributor.authorChristina, M
dc.contributor.authorDe Man, RA
dc.contributor.authorMetselaar, H
dc.date.accessioned2010-09-06T07:21:01Z
dc.date.available2010-09-06T07:21:01Z
dc.date.issued2007
dc.description.abstractWait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<l,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among postransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%. 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among parents who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patiends who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe at wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg. © 2007 AASLD.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationLiver Transplantation, 2007, v. 13 n. 3, p. 349-360 [How to Cite?]
DOI: http://dx.doi.org/10.1002/lt.20981
dc.identifier.doihttp://dx.doi.org/10.1002/lt.20981
dc.identifier.epage360
dc.identifier.hkuros131794
dc.identifier.isiWOS:000244609200008
dc.identifier.issn1527-6465
2011 Impact Factor: 3.386
2011 SCImago Journal Rankings: 0.305
dc.identifier.issue3
dc.identifier.openurl
dc.identifier.pmid17326221
dc.identifier.scopuseid_2-s2.0-33947427581
dc.identifier.spage349
dc.identifier.urihttp://hdl.handle.net/10722/76418
dc.identifier.volume13
dc.languageeng
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
dc.publisher.placeUnited States
dc.relation.ispartofLiver Transplantation
dc.relation.referencesReferences in Scopus
dc.rightsLiver Transplantation. Copyright © John Wiley & Sons, Inc.
dc.subject.meshAdenine - adverse effects - analogs & derivatives - therapeutic use
dc.subject.meshAdult
dc.subject.meshAntiviral Agents - adverse effects - therapeutic use
dc.subject.meshDNA, Viral - blood
dc.subject.meshDrug Resistance, Viral
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshHepatitis B - blood - drug therapy - prevention & control
dc.subject.meshHepatitis B virus - genetics
dc.subject.meshHumans
dc.subject.meshKidney Diseases - chemically induced
dc.subject.meshLamivudine - adverse effects - therapeutic use
dc.subject.meshLiver Transplantation - adverse effects - methods
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPhosphonic Acids - adverse effects - therapeutic use
dc.subject.meshProspective Studies
dc.subject.meshRecurrence - prevention & control
dc.subject.meshWaiting Lists
dc.titleAdefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
dc.typeArticle
Author Affiliations
  1. University of California, San Francisco
  2. UCL
  3. Hopital Paul-Brousse
  4. Scripps Green Hospital
  5. Università degli Studi di Padova
  6. Von-Bodelschwingh-Krankenhaus
  7. University of Tennessee Medical Group
  8. Erasmus University Medical Center
  9. University of Kentucky
  10. Mayo Clinic
  11. null
  12. University of Miami
  13. University of Michigan Hospital
  14. University Hospital
  15. Università degli Studi di Genova
  16. Complejo Hospitalario Universitario de Santiago
  17. Azienda Ospedaliera Consorziale
  18. University of Iowa
  19. Hopital de La Conception
  20. Hopital de Hautepierre
  21. The University of Hong Kong
  22. Universitätsklinikum Leipzig und Medizinische Fakultät
  23. Policlinico Universitario, Udine
  24. Royal Prince Alfred Hospital
  25. Cliniques Universitaires Saint-Luc, Brussels
  26. Hopital Saint-Luc
  27. University of Alberta
  28. University of Pittsburgh Medical Center
  29. null
  30. Mayo Clinic Scottsdale-Phoenix, Arizona
  31. Azienda Ospedaliero - Universitaria di Modena Policlinico
  32. Medizinische Hochschule Hannover (MHH)
  33. Medical College of Virginia
  34. Gilead Sciences Incorporated
  35. Alma Mater Studiorum Università di Bologna
  36. Ospedale Generale di Bolzano
  37. Hospital Universitario La Fe
  38. Toronto General Hospital
  39. Azienda Ospedaliera-Universitaria Pisana
  40. Queen Mary Hospital Hong Kong
  41. Ospedale S. Gionavvi Calibita
  42. University of Cambridge
  43. Klinikum der Universität München
  44. Auckland City Hospital
  45. Universitätsklinikum Hamburg-Eppendorf und Medizinische Fakultät
  46. Università degli Studi di Milano
  47. The Austin and Repatriation Medical Centre
  48. Lahey Clinic Medical Center, Burlington
  49. Hopital Saint-Eloi
  50. null
  51. Hopital de l'Hotel-Dieu CHU Lyon
  52. Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista Di Torino
  53. Hôpital Henri Mondor
  54. Royal Adelaide Hospital
  55. Cedars-Sinai Medical Center
  56. Western Attica General Hospital
  57. Henry Dunant Hospital
  58. Hopital l'Archet
  59. University Hospital of Ghent
  60. Hopital Beaujon